GOLDMAN SACHS GROUP INC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.74 and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$974,629
-33.1%
1,624,923
+45.1%
0.00%
Q2 2023$1,456,288
-23.0%
1,120,222
+4.3%
0.00%
Q1 2023$1,890,481
-51.7%
1,074,137
-13.9%
0.00%
-100.0%
Q4 2022$3,916,136
-33.1%
1,247,177
+4.4%
0.00%0.0%
Q3 2022$5,851,000
-2.4%
1,194,086
-17.6%
0.00%0.0%
Q2 2022$5,997,000
-11.3%
1,448,659
+24.5%
0.00%0.0%
Q1 2022$6,762,000
-25.9%
1,163,887
-4.4%
0.00%
-50.0%
Q4 2021$9,126,000
-38.4%
1,216,896
-26.0%
0.00%
-33.3%
Q3 2021$14,816,000
-20.3%
1,644,324
+5.8%
0.00%
-25.0%
Q2 2021$18,596,000
-23.2%
1,553,541
-19.6%
0.00%
-33.3%
Q1 2021$24,226,000
-37.3%
1,933,462
-21.9%
0.01%
-40.0%
Q4 2020$38,656,000
+121.9%
2,477,114
+34.4%
0.01%
+100.0%
Q3 2020$17,420,000
+20.1%
1,843,335
+13.8%
0.01%
+25.0%
Q2 2020$14,508,000
+63.2%
1,619,211
+16.0%
0.00%
+33.3%
Q1 2020$8,891,000
-17.4%
1,395,696
+8.5%
0.00%0.0%
Q4 2019$10,769,000
-5.9%
1,286,595
+1.7%
0.00%0.0%
Q3 2019$11,444,000
-11.0%
1,264,533
+5.9%
0.00%
-25.0%
Q2 2019$12,860,000
+12.7%
1,194,015
-0.2%
0.00%
+33.3%
Q1 2019$11,408,000
-24.0%
1,195,841
-8.5%
0.00%
-40.0%
Q4 2018$15,005,000
-20.2%
1,307,020
+17.9%
0.01%0.0%
Q3 2018$18,798,000
+160.4%
1,109,015
+118.2%
0.01%
+150.0%
Q2 2018$7,218,000
-45.6%
508,296
-27.3%
0.00%
-33.3%
Q1 2018$13,279,000
-11.2%
698,920
-23.3%
0.00%
-25.0%
Q4 2017$14,948,000
+73.2%
911,512
+58.4%
0.00%
+100.0%
Q3 2017$8,631,000
+879.7%
575,405
+474.4%
0.00%
Q2 2017$881,000
+159.9%
100,176
+53.5%
0.00%
Q1 2017$339,000
-50.5%
65,263
-70.9%
0.00%
Q4 2016$685,000
-15.8%
224,455
+27.8%
0.00%
Q3 2016$814,000
-2.9%
175,636
+21.4%
0.00%
Q2 2016$838,000
+16.9%
144,626
+22.1%
0.00%
Q1 2016$717,000
-94.9%
118,442
-92.3%
0.00%
-100.0%
Q4 2015$14,119,000
+7.6%
1,546,375
-33.5%
0.01%0.0%
Q3 2015$13,117,000
-75.5%
2,325,780
-51.8%
0.01%
-68.8%
Q2 2015$53,512,000
-30.8%
4,825,225
-2.2%
0.02%
-36.0%
Q1 2015$77,356,000
-1.2%
4,933,443
-4.1%
0.02%
+4.2%
Q4 2014$78,281,000
+64.3%
5,146,726
+16.5%
0.02%
+50.0%
Q3 2014$47,645,000
-29.4%
4,417,753
-0.0%
0.02%
-23.8%
Q2 2014$67,480,000
-14.4%
4,419,180
+1.3%
0.02%
-16.0%
Q1 2014$78,856,000
+24.8%
4,361,484
-4.1%
0.02%
+19.0%
Q4 2013$63,168,000
+13.9%
4,547,790
-14.0%
0.02%
+5.0%
Q3 2013$55,468,000
+69.4%
5,287,732
+26.1%
0.02%
+53.8%
Q2 2013$32,751,000
+25093.1%
4,193,557
+19328.1%
0.01%
Q4 2012$130,000
+4.0%
21,585
+5.2%
0.00%
Q3 2012$125,000
+11.6%
20,521
+0.8%
0.00%
Q2 2012$112,000
-25.3%
20,351
-33.6%
0.00%
Q1 2012$150,00030,6280.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Golden State Equity Partners 154,360$897,0000.45%
Rhenman & Partners Asset Management AB 761,429$4,424,0000.44%
Lombard Odier Asset Management (Switzerland) SA 860,702$5,001,0000.39%
WASATCH ADVISORS LP 10,576,997$61,452,0000.30%
Rokos Capital Management LLP 977,663$5,861,0000.27%
KLK CAPITAL MANAGEMENT LLC 44,323$258,0000.26%
Long Focus Capital Management, LLC 340,000$1,975,0000.25%
Vanguard Capital Wealth Advisors 33,380$193,0000.14%
Fort Sheridan Advisors LLC 73,978$430,0000.13%
Delphia (USA) Inc. 20,983$122,0000.09%
View complete list of SANGAMO THERAPEUTICS INC shareholders